Department of Medicinal Chemistry, Institute of Pharmacy, Martin-Luther University of Halle-Wittenberg, 06120 Halle (Saale), Germany.
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Int J Mol Sci. 2022 Jul 7;23(14):7535. doi: 10.3390/ijms23147535.
In addition to involvement in epigenetic gene regulation, histone deacetylases (HDACs) regulate multiple cellular processes through mediating the activity of non-histone protein substrates. The knockdown of HDAC8 isozyme is associated with the inhibition of cell proliferation and apoptosis enhancement in several cancer cell lines. As shown in several studies, HDAC8 can be considered a potential target in the treatment of cancer forms such as childhood neuroblastoma. The present work describes the development of proteolysis targeting chimeras (PROTACs) of HDAC8 based on substituted benzhydroxamic acids previously reported as potent and selective HDAC8 inhibitors. Within this study, we investigated the HDAC8-degrading profiles of the synthesized PROTACs and their effect on the proliferation of neuroblastoma cells. The combination of in vitro screening and cellular testing demonstrated selective HDAC8 PROTACs that show anti-neuroblastoma activity in cells.
除了参与表观遗传基因调控外,组蛋白去乙酰化酶(HDACs)还通过介导非组蛋白蛋白底物的活性来调节多种细胞过程。在几种癌细胞系中,HDAC8 同工酶的敲低与细胞增殖的抑制和凋亡的增强有关。正如几项研究所示,HDAC8 可以被认为是治疗癌症形式(如儿童神经母细胞瘤)的潜在靶点。本工作描述了基于先前报道的强效和选择性 HDAC8 抑制剂取代苯并羟肟酸的 HDAC8 蛋白酶体靶向嵌合体(PROTACs)的开发。在这项研究中,我们研究了合成的 PROTACs 的 HDAC8 降解谱及其对神经母细胞瘤细胞增殖的影响。体外筛选和细胞试验的结合证明了具有选择性的 HDAC8 PROTACs,它们在细胞中具有抗神经母细胞瘤活性。